NYSE$NUVB
Nuvation Bio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Nuvation Bio reported financial results for the third quarter of 2024 and provided a business update.
Nuvation Bio reported a net loss of $41.2 million, or $(0.15) per share, and had cash, cash equivalents, and marketable securities of $549.1 million as of September 30, 2024. The company completed the NDA submission for taletrectinib and presented positive data from Phase 2 TRUST-I and TRUST-II studies.
- Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October.
- Presented positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib at the 2024 European Society of Medical Oncology (ESMO) Congress.
- Appointed Philippe Sauvage as the company’s Chief Financial Officer (CFO) in October.
- Company had a strong balance sheet with cash, cash equivalents, and marketable securities of $549.1 million as of September 30, 2024.
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$727K
Forward guidance
Nuvation Bio anticipates potential FDA acceptance of its NDA submission for taletrectinib by the end of 2024, with a possible U.S. launch as early as mid-2025, and expects to establish a commercial organization.
Tailwinds
- Potential FDA acceptance of NDA submission for taletrectinib by year-end 2024.
- Possible U.S. launch of taletrectinib as early as mid-2025.
- Expectations of establishing a commercial organization.
- Taletrectinib has best-in-class therapeutic potential in advanced ROS1+ NSCLC.
- Potential therapeutic benefit from Nuvation Bio’s product candidates.
Headwinds
- Challenges associated with conducting drug discovery.
- Difficulties or delays in the regulatory process.
- Difficulties in enrolling subjects or manufacturing/acquiring necessary products.
- Emergence or worsening of adverse events or other undesirable side effects.
- Risks associated with preliminary and interim data.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro